

FOR IMMEDIATE RELEASE



## PERTHERA AND LAZAREX CANCER FOUNDATION ANNOUNCE PARTNERSHIP TO ADVANCE PRECISION ONCOLOGY INITIATIVES

*Lazarex and Perthera unite to advance Clinical Trial Access and Enrollment for Cancer Patients*

**Holliston, MA – (February 25, 2020)** [Perthera, Inc.](#), a Biohealth Informatics company with an Oncology Platform proven to advance patient outcomes, and Lazarex Cancer Foundation, an advocacy group whose mission is to improve patient access to cancer clinical trials, have announced the launch of their partnership today. Together, they will be focused on matching and enrolling patients in clinical trials through Lazarex's IMPACT and CARE programs, by utilizing Perthera's treatment-matching Artificial Intelligence (AI) technology and other elements of the Perthera Platform to advance precision medicine for cancer patients.

"We are excited to work with Lazarex Cancer Foundation, a leading organization dedicated to advancing and accelerating patient enrollment in clinical trials," said Gary Gregory, CEO of Perthera, Inc. "Lazarex's passion and mission align perfectly with our innovative technology Platform. Together, we form a powerful team to make a difference for patients, physicians and clinical trial sites."

Perthera's proprietary AI technology allows physicians to utilize comprehensive patient informatics, such as medical history and molecular profile information, to equip physicians with precisely matched therapies that are best suited to advance patient outcomes. Through Perthera's partnership with Lazarex, patients will be matched to the most relevant clinical trials, while expanding patient access and clinical trial enrollment.

"Perthera's Platform has been proven to advance patient outcomes from both an overall and progression-free survival perspective, and also proven to accelerate Clinical Trial enrollment by five times the national average," said Dana Dornsife, Founder and Chairman of Lazarex Cancer Foundation. "Perthera's exceptional capabilities are aligned with the broad reach of our CARE and IMPACT programs and this positions both organizations to deliver exemplary value to patients, physicians and our clinical trial sites across the country."

According to the [Journal of the National Cancer Institute](#), only 2%-4% of newly diagnosed patients participate in clinical trials. Unfortunately, finances and transportation tend to be the largest barriers in the way of these enrollments. [Forbes](#) notes that because of low enrollment, many clinical trials do not meet their targets, resulting in a significant barrier to the advancement of cancer research. Lazarex, founded by members who recognized this significant issue, provides education to patients and has created supportive programs to promote higher patient enrollment in clinical trials.

Perthera's partnership with Lazarex aims to utilize its proven, proprietary Platform to increase clinical trial enrollment and generate real world evidence to advance cancer research & development. To reach out to Perthera regarding their Platform and matched treatment recommendations for oncologists and patients, contact [Hope@Perthera.com](mailto:Hope@Perthera.com) or call (833) 781-7810.

If you are a cancer patient, a caregiver or friend of a cancer patient interested in patient resources or learning more about the possibility of participating in a clinical trial, visit the Lazarex Cancer Foundation's website to learn more about your options <https://lazarex.org/>.

## About Perthera, Inc.

Perthera is the leading Therapeutic Intelligence company advancing cancer care outcomes through its Precision Oncology Platform. Their innovative technology precisely matches cancer patients with ranked therapeutic options, and has been utilized at over 250+ cancer care sites and utilized by over 10% of US Oncologists. Their Precision Oncology Platform, with an AI-driven Therapeutic Intelligence Engine™, has been clinically proven to extend overall and progression-free survival rates by over two-fold for cancer patients. Perthera positions Hospitals and Physicians to harness the power of Precision Medicine to improve patient outcomes and save lives. The Perthera Platform also offers a highly comprehensive Precision Cancer database and an array of services which delivers significant value to Pharma, Drug Development, Clinical Research Organizations and Payers.

To find out more about the Perthera Precision Oncology Platform go to [www.Perthera.com](http://www.Perthera.com).

Follow Perthera on [Twitter](#), [LinkedIn](#), and [Facebook](#).

## About Lazarex Cancer Foundation

Lazarex Cancer Foundation is a publicly funded 501(c)(3) charity focused on the improvement of outcomes in cancer care, giving hope, dignity and life to advanced stage cancer patients and the medically underserved by providing assistance with costs for FDA clinical trial participation, identification of clinical trial options, community outreach and engagement. In its 14 years, Lazarex has assisted over 5,500 patients in clinical trials.

Learn more about Lazarex at <https://lazarex.org/>.

Follow Lazarex Cancer Foundation on [Twitter](#), [LinkedIn](#) and [Facebook](#).

## Media Contacts:

Gary L. Gregory, CEO  
Perthera, Inc.  
Direct: +1.508.397.8885 | Email: [GGregory@Perthera.com](mailto:GGregory@Perthera.com)

Laura Evans Manatos  
Lazarex Cancer Foundation  
Direct: +1.301.379.6028 | [Laura@LauraEvansMedia.com](mailto:Laura@LauraEvansMedia.com)

###

### Safe Harbor Statement:

The statements in the press release that relate to Perthera, Inc. (the "Company") expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.